As PDOs are increasingly adopted as the favored preclinical model for their capacity to faithfully recapitulate patient response to small-molecule chemical perturbations38,39, we next evaluated the requirement for SMARCB1 in this human CRC model (APCc.835-8A>G, KRASG12V). This evidence concerns the gene SMARCB1 and colorectal carcinoma.